Argenica Therapeutics

Name

Argenica Therapeutics

Legal name

Argenica Therapeutics Limited

Website

https://argenica.com.au

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neuroprotective Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stroke & Vascular Neurology (HLAKAIAG)

Keywords

• Neuroprotective therapeutics
• Stroke drug development
• Clinical-stage biotech
• Peptide therapeutics
• Acute ischemic stroke

Headquarters

HQ city

Nedlands

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-commercial clinical stage biotech. The company is developing ARG-007 through clinical trials for acute ischemic stroke and other CNS injuries. Revenue will be generated through product sales upon regulatory approval.
2. Non-Dilutive Funding and Grants: The company receives government grants and R&D tax incentives to support development, including MTPConnect investment, federal government funding, and R&D tax rebates.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Argenica Therapeutics is a clinical-stage drug development company developing ARG-007 (Xaranetide), a proprietary cationic arginine-rich neuroprotective peptide designed to protect brain cells and reduce cell death following acute ischemic stroke, with additional preclinical applications in traumatic brain injury and hypoxic ischaemic encephalopathy. The drug is administered intravenously and is intended for use by first responders in pre-hospital settings and in conjunction with thrombolysis or thrombectomy in hospital emergency departments. The company is currently running a Phase 2 trial in acute ischemic stroke patients across Australia.

Product overview

Argenica Therapeutics is a clinical-stage drug development company with a single lead product, ARG-007 (also called Xaranetide). ARG-007 is a novel neuroprotective peptide being developed for acute ischemic stroke and other brain injuries including traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The company has completed Phase 1 safety trials in healthy volunteers and is currently conducting Phase 2 clinical trials in acute ischemic stroke patients in Australia.

Differentiator

Problem solved

Functional benefit

Products and services

• ARG-007 (Xaranetide) ARG-007 (also known as Xaranetide) is a cationic arginine-rich neuroprotective peptide drug candidate being developed by Argenica Therapeutics for acute ischemic stroke, with additional preclinical applications in traumatic brain injury and hypoxic ischaemic encephalopathy (HIE). It is administered intravenously and is intended for use by first responders in the field to protect brain cells, and alongside thrombolysis/thrombectomy in hospital emergency departments. Currently in Phase 2 clinical trials across Australian emergency departments following completed Phase 1 safety/tolerability studies in healthy volunteers.

Quantifiable outcome

• Greater than 60% preservation of brain tissue for at least 28 days post-stroke in preclinical models
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Western Australian Government / Invest and Trade WAminorGTM or Marketing Partner · 22 June 2026Western Australian government supports Argenica as part of a wider Australian delegation coordinated by MTPConnect attending the BIO International Convention 2026 in San Diego to showcase local companies and connect with international partners, investors, and customers.
• BrainomixcoreTechnology or Integration · 18 December 2025Brainomix partnered with Argenica to analyze data from a Phase II clinical trial of ARG-007 for severe acute ischemic stroke using its AI-powered Brainomix 360 Stroke imaging platform. The analysis confirmed statistically significant and clinically meaningful efficacy with improved neurological outcomes and smaller infarct volumes in treated patients.
• Linear Clinical ResearchcoreStrategic or Co-development Partner · 30 September 2021Linear was engaged to conduct the Phase 1 clinical trial of ARG-007 in healthy volunteers, providing clinical trial management and regulatory expertise.
• University of Western Australia (UWA)coreStrategic or Co-development PartnerARG-007 was developed by researchers at UWA under Professor Bruno Meloni. Ongoing partnership provides continuing research and pipeline development. UWA is the origin institution for the core technology.
• Perron Institute for Neurological and Translational SciencecoreStrategic or Co-development PartnerThe Perron Institute, led by Professor Neville Knuckey, collaborated on the pioneering research that led to ARG-007. Ongoing partnership supports continued research and pipeline development for neuroprotective therapeutics.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Acticor Biotech: Acticor Biotech is a French clinical-stage biotech developing glenzocimab, a novel antibody fragment for acute ischemic stroke, directly competing in the same neuroprotection/thrombectomy adjunct space as Argenica's ARG-007 for emergency stroke treatment.
• ZZ Biotech: ZZ Biotech is developing 3K3A-APC, a recombinant variant of activated protein C with neuroprotective properties for acute ischemic stroke, making it one of the most direct mechanistic comparables to Argenica's peptide neuroprotection approach.
• AB Science: AB Science has clinical programs for masitinib in neurology and stroke-adjacent indications; as a small-cap clinical-stage neuro biotech it shares investment profile comparability with Argenica's stage and therapeutic focus.

Regional players

• Noxopharm Limited: Noxopharm is an ASX-listed clinical-stage Australian biotech developing therapeutics for oncology and neurovascular conditions, making it a regional peer with similar listing profile, capital structure, and clinical-stage dynamics to Argenica.
• Actinogen Medical: Actinogen Medical is an ASX-listed clinical-stage Australian biotech developing neuroprotective/anti-inflammatory therapies (Xanamem) for neurological conditions, sharing the ASX small-cap clinical-stage biotech profile with overlapping CNS therapeutic area focus.
• Pharmaxis Ltd: Pharmaxis is an ASX-listed clinical-stage Australian biotech with CNS-relevant pipeline assets, providing comparability on listing structure, regulatory pathway, and clinical-stage investment dynamics for an Australian biotech peer.

Emerging players

• Healios KK: Healios KK (former parent of Athersys) developed MultiStem cell therapy for ischemic stroke, representing an adjacent modality approach to neuroprotection/repair that competes for the same patient population and partnership attention as ARG-007.
• DiaMedica Therapeutics: DiaMedica is developing DM199 (recombinant KLK1) for acute ischemic stroke, a small clinical-stage biotech targeting the same neuroprotection/recovery clinical setting as Argenica with similar regulatory pathway considerations.

Broad incumbents

• Biogen: Biogen is a large neurological-disease biopharma with stroke and CNS injury pipeline history; as a broad incumbent it sets the comparator framework for partnership economics, M&A multiples, and competitive dynamics in neuro drug development.
• Genentech (Roche): Genentech/Roche developed and markets Activase (tPA) for acute ischemic stroke, making it the standard-of-care incumbent whose protection/adjunct market dynamics shape the addressable opportunity and partnership appetite for neuroprotective peptides like ARG-007.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/argenicat?lang=en
• LinkedInlinkedin.com/company/argenica-therapeutics/?originalSubdomain=au

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Argenica Therapeutics